144 related articles for article (PubMed ID: 17625972)
1. Development of therapeutics for AIDS: structure-based molecular targeting.
Maeda K; Mitsuya H
Tuberculosis (Edinb); 2007 Aug; 87 Suppl 1():S31-4. PubMed ID: 17625972
[TBL] [Abstract][Full Text] [Related]
2. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.
Wilkin TJ; Su Z; Kuritzkes DR; Hughes M; Flexner C; Gross R; Coakley E; Greaves W; Godfrey C; Skolnik PR; Timpone J; Rodriguez B; Gulick RM
Clin Infect Dis; 2007 Feb; 44(4):591-5. PubMed ID: 17243065
[TBL] [Abstract][Full Text] [Related]
3. Impact of PI and NNRTI HAART-based therapy on oral lesions of Brazilian HIV-infected patients.
Ortega KL; Vale DA; Magalhães MH
J Oral Pathol Med; 2009 Jul; 38(6):489-94. PubMed ID: 19453845
[TBL] [Abstract][Full Text] [Related]
4. [Infections with human immunodeficiency viruses. Part II: Antiretroviral drugs, therapeutic options, and diagnostics].
Stock I
Med Monatsschr Pharm; 2011 Jul; 34(7):234-44; quiz 245-6. PubMed ID: 21809598
[TBL] [Abstract][Full Text] [Related]
5. The development of anti-HIV-1 drugs.
Lu XF; Chen ZW
Yao Xue Xue Bao; 2010 Feb; 45(2):165-76. PubMed ID: 21348415
[TBL] [Abstract][Full Text] [Related]
6. The chemokine system and CCR5 antagonists: potential in HIV treatment and other novel therapies.
Dhami H; Fritz CE; Gankin B; Pak SH; Yi W; Seya MJ; Raffa RB; Nagar S
J Clin Pharm Ther; 2009 Apr; 34(2):147-60. PubMed ID: 19250135
[TBL] [Abstract][Full Text] [Related]
7. [Structure-guided molecular-targeting approach for development of AIDS therapeutics].
Maeda K; Mitsuya H
Nihon Rinsho; 2010 Oct; 68(10):1889-95. PubMed ID: 20954335
[TBL] [Abstract][Full Text] [Related]
8. Highly active antiretroviral therapy (HAART) in adults with tuberculosis: current status.
Kwara A; Flanigan TP; Carter EJ
Int J Tuberc Lung Dis; 2005 Mar; 9(3):248-57. PubMed ID: 15786886
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of CCR5-mediated infection by diverse R5 and R5X4 HIV and SIV isolates using novel small molecule inhibitors of CCR5: effects of viral diversity, target cell and receptor density.
Willey S; Peters PJ; Sullivan WM; Dorr P; Perros M; Clapham PR
Antiviral Res; 2005 Nov; 68(2):96-108. PubMed ID: 16157392
[TBL] [Abstract][Full Text] [Related]
10. Activation and coreceptor expression of T lymphocytes induced by highly active antiretroviral therapy in Chinese HIV/AIDS patients.
Zhang ZN; Shang H; Jiang YJ; Liu J; Dai D; Diao YY; Geng WQ; Jin X; Wang YN
Chin Med J (Engl); 2006 Dec; 119(23):1966-71. PubMed ID: 17199940
[TBL] [Abstract][Full Text] [Related]
11. What's new in the fight against AIDS.
Godwin C
RN; 2004 Apr; 67(4):46-52; quiz 53. PubMed ID: 15132046
[No Abstract] [Full Text] [Related]
12. XVI International AIDS Conference: Part 2.
Boyle BA; Cohen CJ; Moyle GJ; Elion R; Sax PE; Frank I
AIDS Read; 2006 Nov; 16(11):581-4, 591-2. PubMed ID: 17152645
[No Abstract] [Full Text] [Related]
13. Recent advances in antiretroviral drugs.
Ghosh RK; Ghosh SM; Chawla S
Expert Opin Pharmacother; 2011 Jan; 12(1):31-46. PubMed ID: 20698725
[TBL] [Abstract][Full Text] [Related]
14. Chemokine (C-C motif) receptor 5 entry inhibitors: new class of drugs for acquired immune deficiency syndrome.
Jacovina A; New M
Mt Sinai J Med; 2008; 75(3):297-8. PubMed ID: 18704982
[No Abstract] [Full Text] [Related]
15. The role of receptors in the HIV-1 entry process.
Jones R; Nelson M
Eur J Med Res; 2007 Oct; 12(9):391-6. PubMed ID: 17933719
[TBL] [Abstract][Full Text] [Related]
16. [HIV protease inhibitors (new possibilities in the treatment of HIV infection and AIDS)].
Bálint GS
Orv Hetil; 1998 Jun; 139(24):1471-4. PubMed ID: 9658865
[TBL] [Abstract][Full Text] [Related]
17. Virological suppression achieved with suboptimal adherence levels among South African children receiving boosted protease inhibitor-based antiretroviral therapy.
Müller AD; Myer L; Jaspan H
Clin Infect Dis; 2009 Jan; 48(1):e3-5. PubMed ID: 19025495
[TBL] [Abstract][Full Text] [Related]
18. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
Laurichesse JJ; Persoz A; Theodorou I; Rouzioux C; Delfraissy JF; Meyer L
HIV Med; 2007 May; 8(4):213-9. PubMed ID: 17461848
[TBL] [Abstract][Full Text] [Related]
19. [Chemokine receptors and its importance in the replication cycle of human immunodeficiency virus: clinical and therapeutic implications].
Azevedo-Pereira JM; Santos-Costa Q
Acta Med Port; 2008; 21(5):497-504. PubMed ID: 19187693
[TBL] [Abstract][Full Text] [Related]
20. Pouncing on the chemokine receptor Chimera.
Mascolini M
J Int Assoc Physicians AIDS Care; 1997 Aug; 3(8):13-24. PubMed ID: 11364629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
